TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Kotani, Daisuke
Kagawa, Yoshinori
Matsubara, Yuki
Bando, Hideaki
Harada, Kazuaki
Takahashi, Naoki
Mihara, Yoshiaki
Nakayama, Izuma
Izawa, Naoki
Kawakami, Takeshi
Masuishi, Toshiki
Hasegawa, Hiroko
Ohta, Takashi
Wakabayashi, Masashi
Yoshino, Takayuki
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[5] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[6] Saitama Canc Ctr, Saitama, Japan
[7] Saiatama Med Univ Int Med Ctr, Hidaka, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] St Marianna Univ Sch Med, Kawasaki, Kanagawa, Japan
[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[13] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[14] Natl Canc Ctr Hosp East, Div Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan
[15] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS264
引用
收藏
页码：TPS264 / TPS264
页数：1
相关论文
共 50 条
  • [1] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [2] A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Garralda, Elena
    Tai, David
    De Braud, Filippo
    Geva, Ravit
    van Bussel, Mark T. J.
    Fiorella Dotti, Katia
    Elez, Elena
    de Miguel, Maria J.
    Litwiler, Kevin
    Murphy, Danielle
    Edwards, Michelle
    Morris, Van Karlyle
    ONCOLOGIST, 2023, : 230 - 238
  • [3] Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
    Osawa, H.
    Shinozaki, E.
    Nakamura, M.
    Ohhara, Y.
    Shindo, Y.
    Shiozawa, M.
    Uetake, H.
    Matsumoto, H.
    Ureshino, N.
    Satake, H.
    Kobayashi, T.
    Suto, T.
    Kitano, S.
    Ohashi, Y.
    Uemura, K.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
    Nakamura, Masato
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
    Kato, T.
    Kotani, D.
    Takashima, A.
    Satoh, T.
    Masuishi, T.
    Komatsu, Y.
    Shiozawa, M.
    Esaki, T.
    Izawa, N.
    Takeuchi, S.
    Bando, H.
    Iwasa, S.
    Hasegawa, H.
    Yamaguchi, T.
    Taniguchi, H.
    Yamada, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
  • [6] Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
    Moro, Kazuki
    Saiki, Takuro
    Sasaki, Kenta
    Matsumoto, Akio
    Zhou, Qiliang
    Nakano, Mae
    Nakano, Masato
    Matsumoto, Yoshifumi
    Shimada, Yoshifumi
    Moriyama, Masato
    Wakai, Toshifumi
    Saijo, Yasuo
    ANNALS OF ONCOLOGY, 2022, 33 : S541 - S541
  • [7] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
    Takashima, Atsuo
    Kotani, Daisuke
    Kato, Takeshi
    Satoh, Taroh
    Masuishi, Toshiki
    Komatsu, Yoshito
    Shiozawa, Manabu
    Esaki, Taito
    Izawa, Naoki
    Takeuchi, Shinji
    Bando, Hideaki
    Iwasa, Satoru
    Hasegawa, Hiroko
    Yamaguchi, Toshifumi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
    Van Cutsem, Eric
    Huijberts, Sanne
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan
    Elez, Elena
    Fakih, Marwan
    Montagut, Clara
    Peeters, Marc
    Yoshino, Takayuki
    Wasan, Harpreet
    Desai, C. Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Christy-Bittel, Janna
    Maharry, Kati
    Sandor, Victor
    Schellens, Jan Hm
    Kopetz, Scott
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1460 - +
  • [9] ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Grothey, A.
    Tabernero, J.
    Taieb, J.
    Yaeger, R.
    Yoshino, T.
    Maiello, E.
    Fernandez, E. Elez
    Casado, A. Ruiz
    Ross, P.
    Andre, T.
    Kato, T.
    Ruffinelli, J.
    Graham, J.
    Van den Eynde, M.
    Vera, R.
    Jean, B.
    Roussel, E. Carriere
    Cahuzac, C.
    Issiakhem, Z.
    Vedovato, J.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S242 - S243
  • [10] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
    Wasan, Harpreet
    Arkenau, Tobias
    Braun, Mike
    Samuel, Leslie
    Graham, Janet
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
12345